The effectiveness of neurodynamic techniques in diabetic peripheral neuropathy.

The effectiveness of neurodynamic techniques on neuropathy severity, tibial nerve’s conduction parameters, quality of life, straight leg raising range of motion in patients with diabetic peripheral neuropathy.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220401054379N1

Enrollment

Registered

2022-10-13

Start date

2022-10-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic peripheral neuropathy. Polyneuropathy in diseases classified elsewhere

Interventions

Intervention 1: 1. Experimental group a) Real tibial nerve’s distal slider technique: This technique will be perfo

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Adults (18-70 years) diagnosed with T2DM by an expert endocrinologist based on their most recent test (within the past 3 months). 2. Patients diagnosed with diabetic peripheral neuropathy based on electrodiagnostic study that was taken by an expert physiatrist. 3. Included patients must have at least 90° hip flexion, full knee extension, and 0° dorsiflexion to 30° plantarflexion

Exclusion criteria

Exclusion criteria: 1. Lasting low back pain, neck pain, and sciatalgia (at least for 3 days) in the last 6 months 2. History of chemotherapy or spinal surgery in the last year 3. History of peripheral nerves' injury or surgery 4. Alcohol or chemical addiction 5. Pregnancy 6. Syphilis, Guillain barre syndrome, rheumatoid arthritis 7. Infection or open wound in the lower limbs 8. Amputation proximal to the metatarsophalangeal joint 9. Complex regional pain syndrome 10. Tarsal tunnel syndrome 11. Severe diabetic peripheral neuropathy (30<MDNS<46) 12. Personal reluctance to paticipate in the present study

Design outcomes

Primary

Measure	Time frame
The Michigan Diabetic Neuropathy Score(MDNS). Timepoint: MDNS as the primary outcome of the present study will be evaluated before the study and at the last session. Method of measurement: The Michigan Diabetic Neuropathy Score(MDNS).	—

Secondary

Measure	Time frame
Tibial nerve conduction velocity. Timepoint: Before the study and at the last session. Method of measurement: Nerve condyution study unit (Neuropack®, s1 MEB-9400, Nihon Kohden, Japan).;Tibial nerve's distal latency. Timepoint: Before the study and at the last session. Method of measurement: Nerve condyution study unit (Neuropack®, s1 MEB-9400, Nihon Kohden, Japan) .;Amplitude of motor nerve action potential. Timepoint: Before the study and at the last session. Method of measurement: Nerve condyution study unit (Neuropack®, s1 MEB-9400, Nihon Kohden, Japan) .;Quality of life. Timepoint: Before the study and at the last session. Method of measurement: Persian localized version of Neuro QoL questionnaire.;Straight leg raising range of motion. Timepoint: Before the study and at the last session. Method of measurement: Manual goniometer.;F-wave latency. Timepoint: Before the study and at the last session. Method of measurement: Nerve condyution study unit (Neuropack®, s1 MEB-9400, Nihon Kohden, Japan) .	—

Measure

Time frame

Tibial nerve conduction velocity. Timepoint: Before the study and at the last session. Method of measurement: Nerve condyution study unit (Neuropack®, s1 MEB-9400, Nihon Kohden, Japan).;Tibial nerve's distal latency. Timepoint: Before the study and at the last session. Method of measurement: Nerve condyution study unit (Neuropack®, s1 MEB-9400, Nihon Kohden, Japan) .;Amplitude of motor nerve action potential. Timepoint: Before the study and at the last session. Method of measurement: Nerve condyution study unit (Neuropack®, s1 MEB-9400, Nihon Kohden, Japan) .;Quality of life. Timepoint: Before the study and at the last session. Method of measurement: Persian localized version of Neuro QoL questionnaire.;Straight leg raising range of motion. Timepoint: Before the study and at the last session. Method of measurement: Manual goniometer.;F-wave latency. Timepoint: Before the study and at the last session. Method of measurement: Nerve condyution study unit (Neuropack®, s1 MEB-9400, Nihon Kohden, Japan) .

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Ebrahim Hashemi

Bagheiat-allah University of Medical Sciences

drhashemi.pmr@gmail.com+98 21 81261

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026